Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats

Research Communications in Molecular Pathology and Pharmacology

Volumn 96, Issue 2, 1997, Pages 227-240

  Yoon, Woo H ^a   Park, Soon J ^b   Kim, In C ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; NEPHRECTOMY; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0030744646     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chanutin, A. and Ferris, E. B., Jr. (1932). Experimental renal insufficiency produced by partial nephrectomy. Arch. Intern. Med. 49: 767-787.
2. Chiou, W. L. (1978). Critical evaluations of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6: 539-546.
3. Chiou, W. L. (1979). New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens. J. Pharm. Sci. 68: 1067-1069.
4. Chiou, W. L. (1980). New calculation method of mean total body clearance of drugs and its application to dosage regimens. J. Pharm. Sci. 69: 90-91.
5. Dinkelaar, R. B., Engels, E. Y., Hart A. A. M., Schoemaker, L. P., Bosch, E. and Chamuleau, R. A. F. M. (1981). Metabolic studies on erythropoietin (Ep): II. The role of liver and kidney in the metabolism of Ep. Exp. Hematol. 9: 796-803.
6. Eatman, F.B., Colburn, W. A., Boxenbaum, H. G., Posmanter, H. N., Weinfeld, R. E., Ronfeld, R., Weissman, L., Moore, J. D., Gibaldi, M. and Kaplan, S. A. (1977). pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J. Pharmacokinet. Biopharm. 5: 481-494.
7. Eckardt, K.-U., Kurtz, A., Hirth, P., Scigalla, P., Wieczorek, L. and Bauer, C. (1988). Evaluation of the stability of human erythropoietin in samples for radioimmunoassay. Klin. Wochenschr. 66: 241-245.
8. Fu, J.-S., Lertora, J. J. L., Brookins, J., Rice, J. C. and Fisher, J. W. (1988). Pharmacokinetics of erythropoietin in intact and anephric dogs. J. Lab. Clin. Med. 111: 669-676.
9. Gibaldi, M. and Perrier, D. (1982). Pharmacokinetics. 2nd ed., Dekker, New York.
10. Hörl, W. H. (1992). Optimal route of administration of erythropoietin in chronic renal failure patients: Intravenous versus subcutaneous. Acta Haematologica 87: 16-19.
11. Jaussaud, P., Audran, M., Gareau, R. L., Souillard, A. and Chavanet, I. (1994). Kinetics and haematological effects of erythropoietin in horses. Vet. Res. 25: 568-573.
12. Jensen, J. D., Madsen, J. K., Jensen, L. W. and Pedersen, E. B. (1994). Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J. Am. Soc. Nephrol. 5: 177-185.
13. Kim, S. H., Choi, Y. M. and Lee, M. G. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm. 21: 1-17.
14. Kindler, J., Eckardt, K.-U., Ehmer, B., Jandeleit, K., Kurtz, A., Schreiber, A., Scigalla, P. and Sieberth H. G. (1989). Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol. Dialys. Tansplant. 4: 345-349.
15. Kinoshita, H., Ohishi, N. and Okazaki, A. (1991). Preparation of iodine labeled recombinant human erythropoietin. Arzneim.-Forsch./Drug Res. 41: 568-570.
16. Kinoshita, H., Ohishi, N., Kato, M., Tokura, S. and Okazaki, A. (1992a). Pharmacokinetics and distribution of recombinant erythropoietin in rats. Arzneim.-Forsch./Drug Res. 42: 174-178.
17. Kinoshita, H., Ohishi, N., Tokura, S. and Okazaki, A. (1992b). Pharmacokinetics and distribution of recombinant human erythropoietin in rats with renal dysfunction. Arzneim.-Forsch./Drug Res. 42: 682-686.
18. Macdougall, I. C., Roberts, D. E., Coles, G. A. and Williams, J. D. (1991). Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet. 20: 99-113.
19. Markham, A. and Bryson, H. M. (1995). Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49: 232-254.
20. McMahon, F. G., Vargas, R., Ryan, M., Jain, A. K., Abels, R. I., Perry, B. and Smith, I. L. (1990). Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76: 1718-1722.
21. Mladenovic, J., Eschbach, J. W., Koup, J. R., Garcia, J. F. and Adamson, J. W. (1985). Erythropoietin kinetics in normal and uremic sheep. J. Lab. Clin. Med. 105: 659-663.
22. Nielsen, O. J. (1990). Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol. Toxicol. 66: 83-86.
23. Okumura, K., Aoki, S., Sugino, T., Ono, T., Nagano, N. and Iba, Y. (1990a). Metabolic fate of TYB-5220 (I). Plasma conocentration in rats after single intravenous administration. Jap. Pharmacol. Ther., 18(S): 129-139.
24. Okumura, K., Aoki, S., Ono, T., Nagano, N. and Iba, Y. (1990b). Metabolic fate of TYB-5220 (II). Plasma concentration, distribution, metabolism and excretion in rats after single intravenous administration. Jap. Pharmacol. Ther., 18(S): 141-162.
25. Okumura, K., Aoki, S., Ono, T., Nagono and Iba, Y. (1990c). Metabolic fate of TYB-5220 (III). Feto-placental transfer and excretion in milk in rats. Jap. Pharmacol. Ther., 18(S): 163-171.
26. Okumura, K., Aoki, S., Ono, T., Nagano, N. and Iba, Y. (1990d). Metabolic fate of TYB-5220 (IV). Plasma concentration, distribution, metabolism, excretion and accumulation in rats aler repeated intravenous administration. Jap. Pharmacol. Ther., 18(S): 173-180.
27. Park, K. J., Yoon, W. H., Shin, W. G. and Lee, M. G. (1997). The effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of azosemide in rabbits. Biopharm. Drug Disposit. 18: 41-52.
28. Salmonson, T., Danielson, B. G. and Wikstrom, B. (1990). The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br. J. Clin. Pharmacol. 29: 709-713.
29. Scigalla P., Hoelk O. and Pahlke W. (1987). Pharmacokinetics of recombinant erythropoietin in normal and uraemic rats. Nephrol. Dialys. Transplant. 2: 389.
30. Shim H. J., Lee E. D., Lee J. J., Kim H. J., Lee S. D., Lee S. H., Kim W. B. and Yang J. (1996). Pharmacokinetics and tissue distribution of recombinant human erythropoietin (DA-3285) in the laboratory animals. J. Appl. Pharmacol. 1: 78-83.
31. Souillard A., Audran M., Bressolle F., Jaussaud P. and Gareau, R. (1996). Pharmacokinetics and haematological parameters of recombinant human etythropoietin after subcutaneous administrations in horses. Biopharm. Drug Disposit. 17: 805-815.
32. Spivak J. L. and Hogans B. B. (1989). The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73: 90-99.
33. Steinberg S. E., Garcia J. F., Matzke G. R. and Mladenovic J. (1986). Eorthropoietin kinetic in rats: Generation and clearance. Blood 67: 648-649.
34. Zhou X.-J. and Vaziri N. D. (1992). Erythtopoietin metabolism and pharmacokinetics in experimental nephrosis. Am. J. Physiol. 263: F812-F815.